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Abstract
Introduction: Randomized controlled trials provide the best method of determining which of two
comparable treatments is preferable. Unfortunately, contemporary randomized trials have become
increasingly expensive, complex and burdened by regulation, so much so that many trials are of
doubtful feasibility.
Discussion: Here we present a proposal for a novel, streamlined approach to randomized trials:
the "clinically-integrated randomized trial". The key aspect of our methodology is that the clinical
experience of the patient and doctor is virtually indistinguishable whether or not the patient is
randomized, primarily because outcome data are obtained from routine clinical data, or from short,
web-based questionnaires. Integration of a randomized trial into routine clinical practice also
implies that there should be an attempt to randomize every patient, a corollary of which is that
eligibility criteria are minimized. The similar clinical experience of patients on- and off-study also
entails that the marginal cost of putting an additional patient on trial is negligible. We propose
examples of how the clinically-integrated randomized trial might be applied in four distinct areas of
medicine: comparisons of surgical techniques, " m e  t o o "  d r u g s ,  r a r e  diseases and lifestyle
interventions. Barriers to implementing clinically-integrated randomized trials are discussed.
Conclusion:  The proposed clinically-integrated randomized trial may allow us to enlarge
dramatically the number of clinical questions that can be addressed by randomization.
Introduction
Consider that participation in a typical randomized trial is
a quite distinct from usual clinical care. From the patients'
point of view, participation in a trial generally requires
additional tests, clinic visits and procedures such as scans
and biopsies, as well as a large number of questionnaires.
For the doctor, having a patient on trial involves a consid-
erable amount of additional paperwork, everything from
documenting eligibility, recording the results of protocol
specific tests and fulfilling regulatory requirements: a
patient on chemotherapy who had a moderately abnor-
mal white count would be followed carefully; if the the
same patient was on a chemotherapy trial, the abnormal
white count would likely necessitate several letters to var-
ious oversight bodies describing the adverse event, the
causal relationship to the investigational agent and the
resulting medical treatment. Participation in a rand-
omized trial is also made distinct by its rarity: a review of
randomized trials in surgery, for example, estimated that
typically fewer than 1% of eligible patients are accrued[1].
Indeed, there is a considerable literature on the difficulties
of accruing patients to clinical trials[2,3].
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Discussion
In this paper, we develop a novel framework for thinking
about and conducting randomized trials. We propose to
integrate randomized trials and routine clinical practice, a
design we term the "clinically-integrated randomized
trial". The key principle is that the clinical experience of the
patient and doctor is virtually indistinguishable whether or not
the patient is randomized. Trial patients go through
informed consent procedures, and certain aspects of care,
such as modifications to the surgical technique used, are
determined by randomization rather than being at the
discretion of the doctor. Otherwise, there are no obvious
differences between the clinical care, follow-up, payment
and documentation requirements between patients who
do and do not participate in the trial.
Integration of a randomized trial into routine clinical
practice also implies that randomization itself is routine,
in other words, there should be an attempt to randomize every
patient. A corollary is that eligibility criteria need to be mini-
mized. The only eligibility criterion should be that the doc-
tor is uncertain about which of the treatments in the trial
would be best for the patient, the "uncertainty princi-
ple"[4].
Ensuring that the clinical experience of patients on trial is
similar to those off-study has an important financial
implication: the marginal cost of putting an additional patient
on trial is negligible. Once the study infrastructure (such as
the study database) is established, and other expenses
associated with trial initiation (such as steering a trial
through scientific review) are accounted for, the only sub-
stantive cost incurred by accrual of a specific patient is the
time involved to inform the patient of the trial and obtain
consent. The costs of each additional randomization is
trivial, especially if conducted by computer; patients then
have to be treated, but this is true whether or not they take
part in the trial. Under the assumption that a fixed propor-
tion of patients will be audited, accrual of a patient will
increase auditing costs, but only by a small amount. This
is in sharp distinction to a traditional randomized trial,
where the extra visits, tests and questionnaires incur sub-
stantial costs, particularly because staff must be hired to
manage trial patients and protocol requirements.
Integration of a trial into routine clinical practice will gen-
erally only be possible if patients, doctors and payers do not
generally have a strong preference for one technique over
another. This would not be the case of trials comparing
very different surgical approaches (e.g. laparoscopic ver-
sus open surgery), active treatment versus active surveil-
lance, or a new procedure that incurs much higher costs
than the traditional approach. Randomized trials of such
comparisons are no doubt important, but will either
include only a subgroup of patients without a strong pref-
erence for one or other technique, or, in the case of the
novel, more expensive treatment, an additional funding
mechanism.
To illustrate the concept of the proposed clinically-inte-
grated randomized trial, and demonstrate how each of its
four elements might be implemented in practice, we will
describe its possible application in four distinct areas: sur-
gery, "me too" drugs, rare diseases and lifestyle interven-
tions.
Example 1: Surgery for prostate cancer
The surgical literature is replete with non-randomized
studies describing modifications to standard surgical pro-
cedures and the results thereof[5,6]. Randomized trials are
much rarer. With respect to radical prostatectomy for
prostate cancer, our focus here, we have only been able to
find only a handful of trials, including a total of fewer
than 1000 patients in total, that have compared different
surgical approaches, such as a retropubic versus perineal
approach[7] or bladder neck eversion versus vesico-ure-
thral anastomosis without bladder neck eversion[8]. In
contrast, simple searches on Medline find well over 2000
non-randomized studies on radical prostatectomy.
One possible reason why such trials are so rare is that the
cost of such trials far outweighs the value of the informa-
tion obtained. For example, imagine that a surgeon devel-
oped a technique which was hypothesized to decrease
rates of impotence, a common side-effect of radical pros-
tatectomy, by about 5%. A suitably powered trial might
require some 3,000 patients. It is not unusual for a trial to
cost upwards of $5,000 per patient [9-11], giving total
costs of at least $15 m. It is implausible that any funding
body would fund a $15 m trial to look for a 5% difference
in potency rates after radical prostatectomy.
A clinically-integrated randomized trial in radical prosta-
tectomy would take the following general form.
1. The patient is first informed about the research during
initial consultations. He is informed that while a lot is
known about the best way to conduct a radical prostatec-
tomy, and although it is known that a radical prostatec-
tomy improves survival, there is considerable doubt about
some technical aspects of the procedure. Accordingly, the
routine practice of the surgeon is to conduct the surgery in
the way that is known to be best for the patient but to ran-
domize certain other aspects of surgery about which there
is uncertainty: the surgeon includes all, or nearly all, of his
or her patients on the randomized trial, and some proce-
dures are only available to trial patients.
2. All patients, whether or not they are on the study, com-
plete a short questionnaire about their baseline urinaryTrials 2009, 10:14 http://www.trialsjournal.com/content/10/1/14
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and erectile function using a web-interface. Data from the
questionnaire is added directly to their medical record.
Use of a web-based interface for patient-reported out-
comes after cancer treatment has been shown to provide
high-quality data[12].
3. If the patient consents to the study, his electronic med-
ical record is flagged. The clinical database then commu-
nicates with a research database which undertakes
randomization.
4. The trial may involve several different arms. For exam-
ple, the trial may, at the same time, examine a novel tech-
nique thought to reduce the risk of shedding of cancer
cells into the circulation and thus cancer recurrence; com-
pare two approaches to nerve-sparing to determine effects
on potency; examine whether preserving an anatomic fea-
ture can improve postoperative urinary function. The trial
might also include randomization within sub-categories
of procedure. For example, patients receiving a care from
a surgeon who uses a laparoscopic approach might be ran-
domized to one of two different laparoscopic devices.
5. Randomization is also stratified by surgeon, such that
each surgeon will treat approximately equal numbers of
patients with each technique. Randomization also uses a
minimization ("biased coin") approach to ensure broad
comparability of prognostic factors between groups[13]:
this important because one surgeon may see only limited
numbers of patients. Data on prognostic factors is
obtained directly from the electronic medical record.
6. The results of randomization are sent directly to the
electronic medical record with a copy to the surgeon by
email. The electronic medical record would also record
that the patient had been randomized. After surgery, the
surgeon uses tick boxes on the electronic medical record
to document the actual procedures used during the sur-
gery.
7. Patients are sent emails at home every few months. This
provides a link to a secure website containing an elec-
tronic questionnaire about urinary and erectile function.
Patient's responses to the questionnaire are uploaded
directly to the patient's electronic medical record. Patients
without home Internet access can access the website using
a hospital computer when they return for routine follow-
up visits. Exactly the same emails are sent to patients who
do not consent to the trial, as they are a standard part of
clinical follow-up.
8. The study statistician can download data directly from
patient's electronic medical record by running a query
through the central study database. The query would auto-
matically de-identify data so that patient privacy is pro-
tected. All pertinent endpoints should be directly
available from the patient record including cancer charac-
teristics, such as stage and grade; surgical details such as
operating time, blood loss, length of stay, complications
and surgical margins; oncologic results, such as cancer
recurrence; functional outcomes, such as urinary and erec-
tile function, obtained from the electronic questionnaires.
9. The trial can open and close arms independently. For
example, a comparison of two devices, the primary end-
point of which is operating time, may require far fewer
patients than a study with cancer recurrence as an end-
point. Similarly, an arm could close if a treatment was
found to be harmful during the trial. Accordingly, the clin-
ically-integrated trial would consist of a single master pro-
tocol, continuing over many years. This would drastically
reduce the time and effort required to test new questions.
This is not a trivial consideration: it has been estimated
that opening a clinical trial through Cancer and Leukemia
Group B, one of the main cooperative groups that conduct
multicenter trials in cancer, typically requires 370 separate
steps and about two years[14].
Note that the trial is of factorial design, that is, patients
can receive one intervention, a different intervention,
both or neither. This allows the study hypotheses to be
addressed with far fewer patients. A factorial design is
most appropriate when there is no interaction between
treatment arms, that is, when the effects of one surgical
modification, say to protect potency, are similar in
patients with and without the other experimental modifi-
cation, say to improve continence rates. We believe that
this condition will be met for most surgical modifications.
Such a design might allow either patients or surgeons to
"opt out" of particular comparisons. For example, if a sur-
geon felt that a particular procedure for preserving
potency was associated with excess risk of recurrence, that
surgeon's patients would always be assigned so that they
did not receive that procedure; however, these patients
could still be randomized with respect to other compari-
sons in the trial, such as techniques to improve conti-
nence.
Example 2: Rare disease and "me too" drugs
Rare diseases and "me too" drugs paradoxically present
the physician with a similar problem: choosing a therapy
out of a bewildering array of possibilities. For rare diseases
this is because difficulties of accruing patients to large tri-
als mean that there are often only a few treatments that
have been proven to be effective, leaving the physician to
try unproven approaches for patients who do not
respond; in the case of "me too" drugs, there are many
treatments known to be effective, but often none has been
proven superior to another.Trials 2009, 10:14 http://www.trialsjournal.com/content/10/1/14
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To illustrate how a clinically-integrated randomized trial
could be of benefit, take the case of a patient with newly
diagnosed depression. The patient's doctor recommends
antidepressant medication, and explains why this might
help. The doctor then states that although all prescription
antidepressants are known to work, exactly which is most
effective is unknown, and proposes that the patient takes
part in a randomized trial in which the drug is chosen at
random. If the patient agrees, he or she would complete a
depression questionnaire. The doctor, or office assistant,
would then access a secure study website and enter a lim-
ited amount of basic patient data, which would include
any co-morbidities, age and contact details, as well as the
results of the depression questionnaire. The study data-
base would then randomize the patient and present a
"results screen" showing the allocated drug. This drug is
then prescribed in the normal way, with the patient col-
lecting the drug at the local pharmacy. The patient is then
sent an email at 6 and 12 weeks with links to the depres-
sion questionnaire and a brief questionnaire about side-
effects. The trial might also contact the patient at long-
term follow-up, say 12 – 24 months, and include ques-
tions about depression, drug compliance and use of other
therapies. The results of the questionnaire would be sent
to the patient's doctor so that he or she could adjust the
patient's care appropriately, for example, by changing
treatment if response was poor (indeed, one advantage for
doctors to participate in the trial might be that such a sys-
tem might be made available to all their patients, whether
or not they took part). Outcomes such as hospitalization
or death – important in a comparison of say, different sta-
tin drugs – could be obtained by computerized linkage to
national databases. This approach has been shown to fea-
sible and accurate[15] and has been used in the analysis
of a large randomized trial[16].
A similar schema could be used for the treatment of a rare
disease: explanation to the patient that the most appropri-
ate course of treatment is unknown; web-based comple-
tion of baseline data and randomization; treatment given
by the doctor according to the results of randomization;
follow-up via email. Such a trial could be conducted
worldwide, involving all major centers where the rare dis-
ease is treated, although this would require worldwide
agreement on which interventions to test.
Example 3: Lifestyle interventions
There is a bewildering array of diets for weight loss, and
the US National Institutes of Health has accordingly spon-
sored several major randomized trials. While no doubt
providing valuable information, these trials have been rel-
atively small and expensive (for example, 311[17] or
160[18] patients accrued at a cost of $1 – $2.5 m [data
from authors]). A sample size of 300 is somewhat less of
a drop in the bucket of the approximately 50 million
Americans who attempt to lose weight each year[19]. A
clinically-integrated randomized trial would allow
patients to log on to a website, read appropriate informa-
tion and warnings about the trial, take a short test to con-
firm their understanding, provide baseline information –
such as age, weight, previous diet history and perhaps a
psychological questionnaire – and then be randomized to
one of a number of different weight loss programs. Com-
pliance and weight changes would then be assessed by
patient self-report; patients would also have the opportu-
nity to enter other data, such as cholesterol or blood pres-
sure, if these were assessed in routine care. A similar
methodology could be used for smoking cessation, or
exercise regimens.
Incentives for doctors and patients
There are several incentives that could be offered to doc-
tors to encourage them to take part in a clinically-inte-
grated randomized trial. In the case of the surgery trial,
where many of the trial doctors will be academics, an
excellent incentive would be to allow all participants
access to deidentified raw study data. This would allow
these doctors to test any additional, secondary hypotheses
of interest to their scientific work. In the case of the "me
too" drug trials, and trials of rare diseases, many of the
participating doctors will be in the community and offers
of data sharing are unlikely to be highly valued. A modest
payment, to compensate for the minor additional work
involved randomizing a patient, might comprise a suffi-
cient incentive for many doctors.
In addition, response adaptive allocation ("play-the-win-
ner") might be considered[20]. This works as follows: let
us imagine that the depression trial randomizes between
four drugs: A, B, C and D. For the first 100 patients or so,
each patient has an exact 25% chance of receiving any par-
ticular treatment. The results of the first 100 patients are
then analyzed. Now assume that response rates were 50%,
60%, 50% and 40% for drug A, B, C and D respectively.
The randomization scheme is then adjusted so that
patients have a slightly higher chance (say 30%) of being
randomized to drug B, which current data suggests is the
most effective, and a slightly lower chance (say 20%) of
being randomized to the currently least effective drug D.
These randomization probabilities can be updated con-
tinuously as the trial progresses. Although the results are
not made public, doctors could say to their patients, "I
really don't know which is the best drug, nobody does,
but if we put you on the trial, you have a higher chance of
getting the most effective treatment – based on the experi-
ences of all the patients that have been treated so far –
compared to if I just take a guess and choose a treatment
for you". Similarly, a trial comparing diets would
undoubtedly be more attractive to patients if they had a
higher chance of being randomized to the diet which hadTrials 2009, 10:14 http://www.trialsjournal.com/content/10/1/14
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currently led to greatest weight loss. Response adaptive
allocation can be inefficient compared to equal randomi-
zation, and some authors have claimed that it subverts
equipoise, the ethical imperative behind randomiza-
tion[21] (although other authors have argued the oppo-
site[22]). Nonetheless, the technique could be considered
as a way to encourage patient and doctor participation.
The use of web-based questionnaires may also be seen as
a benefit to patients. Patients like to see how they are
doing, and the web system could be programmed to pro-
vide feedback to patients as to their progress in an attrac-
tive and user friendly manner.
That said, the design of the clinically-integrated trial is
such that important incentives may be unnecessary. We
typically use incentives to get someone to do something
they would not otherwise want to do, like undergo testing
or fill in lengthy questionnaires. If patient care is essen-
tially unaltered by the trial, the question of incentives
becomes somewhat moot especially if randomization is
routine for all patients.
Barriers to clinically-integrated randomized trials
We see four potential barriers to adoption of clinically-
integrated randomized trials: methodologic, technical,
practical and regulatory. The methodologic issue is that
clinically-integrated randomized trials ask about the effec-
tiveness of treatments in routine clinical practice. This is
generally the domain of what are known as "pragmatic"
trials, which cannot have the sort of rigorous controls
associated with "explanatory" trials[23], such as blinding
or careful outcome assessment (for example, in a diet trial,
patients would weigh themselves). Instead, one would
need to trust that there would not be important prefer-
ences – leading to bias – between different similar alterna-
tives, and that the sort of large sample sizes possible with
clinically-integrated trials – 10, 20 or 50 fold greater than
with traditional trials – would offset any increase in vari-
ance associated with sub-optimal outcome assessment, or
the possibility of cheating by a minority of participants
with a vested interest in the results.
The technical issues are distinct for the surgery trial as
compared to trials of "me too" drugs, rare diseases or life-
style interventions. The surgery trial requires integration
of the electronic medical record and the research database.
This requires that all institutions taking part in the trial
use either a similar form for the electronic medical record,
or design a special interface between the institution's
medical record system and that of the trial. In the case of
prostate cancer, many institutions currently use an elec-
tronic medical record system known as CAISIS[24] that
could easily be adapted for use in a clinically-integrated
randomized trial. Institutions not using CAISIS would
require special programming code to be written to allow
communication between the research and clinical data-
bases. This can be expensive, but would only need to be
done once for each institution. For trials of "me too"
drugs, rare diseases or lifestyle interventions, the trialists
would need to establish a website with separate interfaces
for physicians, patients and study investigators. Again,
this might incur considerable costs, but those costs would
only need to be paid once and would certainly not
approach the many millions of dollars currently associ-
ated with large trials.
A practical limitation concerns patient access to the Inter-
net. Yet Internet penetration is deep and growing – in
2007 about 61% of British households had Internet
access, a proportion growing by 7% per year[25] – and tel-
ephone systems can be used to obtain symptoms for
patients without Internet access: a recorded message asks,
for example, for patients to rate their pain on a 0 – 6 scale,
and the patient presses 0 – 6 on the telephone key pad as
appropriate.
A limitation related to the Internet is whether patients
might give biased or even maliciously false responses.
Although we do not think that patient bias would be
important for most clinically integrated trials – for exam-
ple, we do not think patients would have a preference
between different modifications of surgical technique – it
is possible that trials of drugs, or of diets, might be subject
to Internet abuse. For example, proponents of a diet might
sign up to a trial and claim to have lost weight if rand-
omized to their favorite diet and to have gained weight
otherwise. We think that a limited number of simple steps
could reduce the possibility of fraud. First, patients con-
senting through the web could be sent by mail to their
home a code number to be entered the first time that out-
come information is entered. This would prevent a single
individual from submitting multiple "ghost" entries as the
web system would easily recognize repeat addresses. Sec-
ond, patients would be asked if they would be willing to
be audited, which would involve face-to-face contact with
a member of the study team. Although, a proportion of
patients would indeed be audited, the primary purpose of
the audit would be to explore any unusual patterns of
those unwilling to be contacted further. That said, clini-
cally-integrated randomized trials are not blinded, and so
are prey to similar considerations of bias as other open
label trials. If the investigators believe that the risk of bias
from lack of blinding outweighs the benefits of large sam-
ple sizes, then a clinically-integrated randomized trial is
not an appropriate methodology.
Perhaps the most significant barrier to clinically-inte-
grated randomized trials is regulatory and concerns ethi-Trials 2009, 10:14 http://www.trialsjournal.com/content/10/1/14
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cal oversight. Although in the surgery trial it would be
feasible to obtain ethical approval from all participating
centers, trials of "me too" drugs or, particularly, rare dis-
eases, are likely to involve very large numbers of geo-
graphically diverse sites, many of which may enter only
one or two patients. It is simply not feasible to attempt to
obtain local ethical approval separately for all doctors
who might enter patients in such a trial. The obvious solu-
tion would be for national or regional oversight entities to
grant waivers to allow physicians to enter patients on tri-
als without local ethical approval if the trial as a whole has
been approved by a reputable review committee. Whether
local ethical committees would be willing to relinquish
oversight is another matter. Moreover, for a trial of a rare
disease conducted globally, it might be complex to obtain
ethical approval for all countries involved, even if local
approval was not needed and only a single national
approval required. In the case of lifestyle trials, where
patients can enter themselves on study, matters of ethical
oversight remain unclear: who is responsible for oversee-
ing a trial where thousands of patients sign on to a trial via
a website?
Conclusion
The current proposal involves a novel way of thinking
about and conducting clinical trials. To see why this is
unusually innovative, we might consider what fundamen-
tal innovations have been made to randomized trials
since their inception. There have been relatively few: clus-
ter randomization has been developed to deal with inter-
ventions that can affect more than one patient at a time,
and group sequential methods have allowed ethically
appropriate (and scientifically sound) evaluation of
interim results. Perhaps the most fundamental innovation
to randomized trials that has become a common part of
research practice is the "large, simple trial"[4]. The clini-
cally-integrated randomized trial has much in common
with the large, simple trial: moderate effects are clinically
important; to detect such effects requires large trials; to be
large, trials must be simple. However, the clinically-inte-
grated randomized trial is distinct in its emphasis on mak-
ing randomization part of routine clinical care and in the
attempt to randomize every patient (this is analogous, but
importantly different, to Chalmers' call to "randomize the
first patient"[26]). Moreover, large, simple trials have gen-
erally been used to determine whether treatments work at
all (e.g., fibrinolytics for heart attack) rather than to eval-
uate different modifications to a therapy of known effec-
tiveness. The development of information technology is
also central to the clinically-integrated randomized trial as
it allows the incorporation of patient-reported outcomes;
typical large, simple trials have used mortality as an end-
point.
Our proposal is neither a replacement for more tradi-
tional designs (see table 1) nor a "one-size-fits-all" meth-
odology: many design decisions would need to be taken
irrespective of whether trialists chose a clinically-inte-
grated or more traditional design. Take, for example,
whether only highly experienced surgeons would be eligi-
Table 1: Features of trials appropriate for clinically-integrated versus more traditional randomized trials.
Clinically-integrated randomized trial Traditional randomized trial
Tests, procedures, questionnaires All data needed to address the study question 
would be of value for the clinician during routine 
follow-up. All tests, procedures and questionnaires 
would be given to patients irrespective of 
participation.
Example: A test for cancer recurrence.
Some data required to answer study-specific questions 
would not be taken during routine care.
Example: blood draw for a molecular marker thought to 
predict response to treatment.
Treatments Patients very unlikely to have strong preferences for 
one or other treatment.
Example: Two alternative suturing techniques during 
surgery.
Many patients may have a strong preference for one or 
other treatment.
Example: Radical versus breast conserving surgery.
Comparisons Can only compare two active treatments.
Example: Two widely used anti-depressants of proven 
value.
May compare an active treatment to placebo or no 
treatment control.
Example: Novel anti-depressant versus placebo.
Patients Most patients are randomized. Only a proportion of patients are randomized.
Eligibility criteria Eligibility criteria should be minimized.
Example: all patients undergoing radical prostatectomy 
are eligible.
Eligibility criteria can be restrictive.
Example: restrictions on comorbidities in a trial of a novel 
drug.
Information technology Trial depends heavily on information technology. Trial can be lo-tech.Trials 2009, 10:14 http://www.trialsjournal.com/content/10/1/14
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ble compared to all surgeons; which questionnaires
would be given and when; and how crossover between
different drugs would be handled statistically: such ques-
tions are not determined by the degree of clinical integra-
tion of the trial but by the specific research questions
being addressed.
We believe that the randomized trial is the best method
for determining the optimal treatment from comparable
alternatives, be they modifications to surgery, "me too"
drugs, treatments for rare diseases or diets for weight loss.
Yet contemporary randomized trials have become increas-
ingly expensive, complex and burdened by regulation, so
much so that many trials are of doubtful feasibility. Our
proposed clinically-integrated randomized trial is a
streamlined approach to randomized trials that may allow
us to enlarge dramatically the number of clinical ques-
tions that can be addressed by randomization. That said,
our proposal is just that, a proposal: there has been no
practical experience of the methodology and we do not
know, amongst other things, whether doctors would agree
to take part in clinically-integrated randomized trials,
whether patients would consent to them, whether the tri-
als would be approved by ethical bodies and whether the
trials would indeed be low cost. We intend to experiment
with the methodology in the near future by conducting a
trial of modifications to radical prostatectomy.
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